Standard BioTools Announces Senior Leadership Changes

Management Changes - Jeffrey Black, Chief Financial Officer, will resign effective August 31, 2024, to pursue another opportunity [1] - Alex Kim, Chief Operating Officer and co-founder, will serve as interim Chief Financial Officer starting September 1, 2024 [1] - Sean Mackay, recently appointed Chief Business Officer, will take on additional responsibilities including product management, marketing, and investor relations [2] Leadership Statements - Michael Egholm, President and CEO, expressed confidence in Alex Kim's leadership and strategic planning capabilities for the interim CFO role [3] - Egholm acknowledged Jeffrey Black's contributions to building a strong finance function and wished him well in his future endeavors [3] - Black expressed pride in his time at Standard BioTools and confidence in the company's future success [3] Company Overview - Standard BioTools Inc. (Nasdaq: LAB) is known for its next-generation technologies that aid biomedical researchers in developing medicines [5] - The company focuses on providing insights in health and disease through proprietary mass cytometry and microfluidics technologies [5] - Standard BioTools collaborates with various research and clinical laboratories globally, addressing needs in translational and clinical research, particularly in oncology and immunology [5]